Cantor Fitzgerald Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of $100
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Janux Therapeutics (NASDAQ:JANX) with an Overweight rating and a price target of $100.
March 20, 2024 | 9:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald initiated coverage on Janux Therapeutics with an Overweight rating and set a price target of $100.
The initiation of coverage by a reputable analyst with a positive Overweight rating and a high price target of $100 suggests a strong bullish outlook for Janux Therapeutics. This is likely to generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100